<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511639</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001JIT36T</org_study_id>
    <secondary_id>2013-004153-24</secondary_id>
    <nct_id>NCT02511639</nct_id>
  </id_info>
  <brief_title>Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients</brief_title>
  <acronym>MAIN-A</acronym>
  <official_title>MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare maintenance Aromatase Inhibitors (AIs) + everolimus
      with Aromatase Inhibitors alone after 1st line chemotherapy in patients with HR+ metastatic
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is:

        -  to compare the progression free survival (PFS) of AIs/everolimus to AIs administered as
           maintenance therapy in HR+ advanced breast cancer patients with disease control
           (Complete Response (CR), Partial Response (PR) or Stable Disease (SD))after 1st line
           chemotherapy.

        -  To evaluate the overall survival

        -  To assess the safety profile

        -  To evaluate the response rate
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 2 years after randomisation</time_frame>
    <description>PFS is defined as the time from randomization to the first documentation of objective disease progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years after randomisation</time_frame>
    <description>Overall survival is defined as the interval between the date of randomization and the date of patient death due to any cause, or the last date the patient was known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 12 weeks during treatment, up to 2 years after randomisation</time_frame>
    <description>Responses will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria only for patients with measurable disease at the time of study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Baseline and every 4 weeks during treatment, up to 2 years after randomisation</time_frame>
    <description>Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI -CTCAE), version 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A: Everolimus &amp; Aromatase inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Aromatase inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus is formulated as tablets of 10 mg strength for oral administration.</description>
    <arm_group_label>Arm A: Everolimus &amp; Aromatase inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors</intervention_name>
    <description>Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.</description>
    <arm_group_label>Arm A: Everolimus &amp; Aromatase inhibitors</arm_group_label>
    <arm_group_label>Arm B: Aromatase inhibitors</arm_group_label>
    <other_name>Exemestane</other_name>
    <other_name>Letrozole</other_name>
    <other_name>Anastrozole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years old women with metastatic breast cancer

          2. Histological confirmation of hormone-receptor positive (defined as at least 10% of
             estrogen receptor (ER) and/or progesterone receptor (PgR) positivity) and human
             epidermal growth factor receptor 2 (HER2) negative (score 0-1+ in immunohistochemistry
             or FISH negativity) breast cancer

          3. Postmenopausal status

          4. One line of chemotherapy for metastatic disease; patients must have received a minimum
             of 6 cycles of chemotherapy in order to be eligible, and must have obtained disease
             control (CR or PR od SD)

          5. Eastern Cooperative Oncology Group (ECOG) Performance status &lt; 2

          6. Adequate bone marrow and coagulation function

          7. Adequate liver function

          8. Adequate renal function

          9. Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5 ×
             upper limit of normal (ULN). In case one or both of these thresholds are exceeded, the
             patient can only be included after initiation of statin therapy or other lipid
             lowering drugs (eg fibrates), and when the above mentioned values have been achieved

         10. Fasting glucose &lt; 1.5 × ULN

         11. Written informed consent obtained before any screening procedure and according to
             local guidelines.

        Exclusion Criteria:

          1. HER2-overexpressing patients by local laboratory testing (immunohistochemistry 3+
             staining or in situ hybridization positive)

          2. Previous treatment with mammalian target of rapamycin (mTOR) inhibitors

          3. Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin)

          4. More than one chemotherapy line for metastatic disease

          5. Treatment with angiogenetic compounds as maintenance therapy (eg. bevacizumab)

          6. Radiotherapy within four weeks prior to enrollment except in case of localized
             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can
             then be completed within two weeks prior to enrollment. Patients must have recovered
             from radiotherapy toxicities prior to enrollment

          7. Symptomatic central nervous system metastases

          8. Patients with a known history of HIV positivity

          9. Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose
             warfarin and acetylsalicylic acid or equivalent, as long as the international
             normalized ratio (INR) is ≤ 2.0)

         10. Any severe and / or uncontrolled medical conditions such as:

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction ≤6 months prior to enrollment, serious uncontrolled cardiac arrhythmia

               -  Uncontrolled diabetes as defined by fasting serum glucose &gt; 1.5 × ULN

               -  Acute and chronic, active infectious disorders and nonmalignant medical illnesses
                  that are uncontrolled or whose control may be jeopardized by the complications of
                  this study therapy

               -  Impairment of gastrointestinal function or gastrointestinal disease that may
                  significantly alter the absorption of study drugs (e.g., ulcerative disease,
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

               -  Significant symptomatic deterioration of lung function. If clinically indicated,
                  pulmonary function tests including measures of predicted lung volumes, diffusion
                  capacity of lung for carbon monoxide (DLco) and O2 saturation at rest on room air
                  should be considered to exclude restrictive pulmonary disease, pneumonitis or
                  pulmonary infiltrates.

         11. Patients who test positive for hepatitis B or C (patients who test negative for
             hepatitis B virus (HBV)-DNA, HBsAg, and HBcAb but positive for HBsAb with prior
             history of vaccination against Hepatitis B will be eligible)

         12. Patients being treated with drugs recognized as being strong inhibitors or inducers of
             the isoenzyme Cytochrome P3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole,
             Itraconazole, Voriconazole, Ritonavir, Telithromycin) within the last 5 days prior to
             enrollment

         13. History of non-compliance to medical regimens

         14. Patients unwilling to or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierfranco Conte, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology 2, Istituto Oncologico Veneto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Luca De Salvo, MD, PhD</last_name>
    <phone>00390498215710</phone>
    <email>gianluca.desalvo@ioveneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Cascinu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Engles Profili&quot; Fabriano A.S.U.R. MARCHE</name>
      <address>
        <city>Fabriano</city>
        <state>AN</state>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosarita Silva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori &quot;Giovanni Paolo II&quot; IRCCS Ospedale Oncologico di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Lo Russo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Zamagni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL Brindisi &quot;Antonio Perrini&quot;</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Cinieri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Amoroso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.S.O. S.Croce e Carle di Cuneo</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ornella Garrone, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria &quot;Policlinico - Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Soto Parra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU San Martino IST Istituto Nazionale per la Ricerca sul Cancro IRCCS</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Del Mastro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia di Grosseto</name>
      <address>
        <city>Grosseto</city>
        <state>GR</state>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Bengala, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori IRCCS</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Mariani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale G da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonino Musolino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Azienda Ospedaliera S.M. Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Santa Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Ferro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. - Fondazione del Piemonte per l'Oncologia</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Montemurro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Puglisi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULSS 6 Vicenza</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcella Gulisano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore - Don Calabria</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <zip>37042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Gori, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore - AOUI - Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Molino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Morandi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Oncologico Veneto IRCCS</investigator_affiliation>
    <investigator_full_name>Pierfranco Conte</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hormone receptor positive</keyword>
  <keyword>HER2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

